Banc of America Securities downgraded the shares to 'Neutral' from 'Buy,' while Matrix Research downgraded the stock to 'Hold' from 'Buy.'
As GenomeWeb News reported yesterday, Serologicals said that first-quarter revenues slipped 2.8 percent as R&D spending jumped 11 percent and profits nearly doubled.
One day earlier, the company said it would be acquired by Millipore for $1.4 billion.